Elotuzumab in the treatment of relapsed and refractory multiple myeloma

2021 ◽  
Author(s):  
Sebastian Grosicki ◽  
Martyna Bednarczyk ◽  
Agnieszka Barchnicka ◽  
Olga Grosicka
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibodies ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
Clinical Studies ◽  
Mechanisms Of Action ◽  
Incurable Disease ◽  
The Us ◽  
Us Fda ◽  
Humanized Monoclonal Antibodies

Multiple myeloma (MM) is still considered an incurable disease. However, drugs with different mechanisms of action that can improve the efficiency of treatment offer hope. Still, there are concerns about an unacceptable increase in toxicity with such regimens. The results of recently published clinical studies of elotuzumab in combination with lenalidomide/dexamethasone or pomalidomide/dexamethasone confirm previous hopes to improve the effect of that treatment. Humanized monoclonal antibodies aimed at SLAMF7 stimulate natural killer cells to fight against MM cells. Elotuzumab used in combination with lenalidomide/dexamethasone or with pomalidomide/dexamethasone is approved by the US FDA to treat patients with relapsed and/or refractory MM. The article is a summary of the recent knowledge about the possibility of using elotuzumab in the treatment of relapsed and/or refractory MM and shows its potential uses in the future.

scholarly journals Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment

2020 ◽  
Vol 13 (12) ◽  
pp. 426
Author(s):  
Sonia Morè ◽  
Maria Petrucci ◽  
Laura Corvatta ◽  
Francesca Fazio ◽  
Massimo Offidani ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibodies ◽  
Preliminary Data ◽  
Clinical Studies ◽  
Hematologic Malignancy ◽  
Therapeutic Options ◽  
Phase Iii ◽  
Incurable Disease ◽  
Phase Iii Trials ◽  
Phase Ii And Iii

Multiple myeloma is a complex hematologic malignancy, and despite a survival improvement related to the growing number of available therapeutic options since 2000s, it remains an incurable disease with most patients experiencing relapse. However, therapeutic options for this disease are constantly evolving and immunotherapy is becoming the mainstay of the therapeutic armamentarium of Multiple Myeloma (MM), starting with monoclonal antibodies (MoAbs) as elotuzumab, daratumumab and isatuximab. Elotuzumab, the first in class targeting SLAMF7, in combination with lenalidomide and dexamethasone and daratumumab, directed against CD38, in combination with Rd and with bortezomib and dexamethasone (Vd), have been approved for the treatment of relapsed/refractory MM (RRMM) after they demonstrated excellent efficacy. More recently, another anti-CD38 MoAb named isatuximab was approved by FDA in combination with pomalidomide-dexamethasone (Pd) in the same setting. Many phase II and III trials with regimens containing these MoAbs are ongoing, and when available, preliminary data are very encouraging. In this review we will describe the results of major clinical studies that have been conducted with elotuzumab, daratumumab and isatuximab in RRMM, focusing on phase III trials. Moreover, we will summarized the emerging MoAbs-based combinations in the RRMM landscape.

Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells

2021 ◽  
Vol 160 ◽  
pp. 103261
Author(s):  
Mélanie Gauthier ◽  
Caroline Laroye ◽  
Danièle Bensoussan ◽  
Cédric Boura ◽  
Véronique Decot
Keyword(s):  
Monoclonal Antibodies ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
Tumor Cells ◽  
Killer Cells

The therapeutic role of natural killer cells in multiple myeloma

2019 ◽  
Vol 2 (2) ◽  
pp. e49 ◽  
Author(s):  
Ghulam Rehman Mohyuddin ◽  
Muzaffar H. Qazilbash
Keyword(s):  
Multiple Myeloma ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
Killer Cells ◽  
Therapeutic Role

Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model

2007 ◽  
Vol 35 (12) ◽  
pp. 1839-1846 ◽  
Author(s):  
Evren Alici ◽  
Kyriakos V. Konstantinidis ◽  
Tolga Sutlu ◽  
Alar Aints ◽  
Gösta Gahrton ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
Killer Cells

scholarly journals Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment

2015 ◽  
Vol 75 (22) ◽  
pp. 4766-4777 ◽  
Author(s):  
Andrea Ponzetta ◽  
Giorgia Benigni ◽  
Fabrizio Antonangeli ◽  
Giuseppe Sciumè ◽  
Emilio Sanseviero ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
Killer Cells
Sign in / Sign up

Export Citation Format

Share Document